A new mouse model for marfan syndrome presents phenotypic variability associated with the genetic background and overall levels of Fbn1 expression

PLoS ONE

Volumn 5, Issue 11, 2010, Pages

  Lima, Bruno L ^a   Santos, Enrico J C ^a,b   Fernandes, Gustavo R ^a   Merkel, Christian ^a   Mello, Marco R B ^a,c   Gomes, Juliana P A ^a   Soukoyan, Marina ^a   Kerkis, Alexandre ^a,b   Massironi, Silvia M G ^a   Visintin, José A ^a   Pereira, Lygia V ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Celltrovet   (Brazil)

^c FEDERAL RURAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRILLIN 1; ACTIN BINDING PROTEIN; FIBRILLIN;

129 MOUSE; ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA WALL; ARTICLE; C57BL 6 MOUSE; CONTROLLED STUDY; DISEASE SEVERITY; EMBRYO; EMPHYSEMA; EPIGENETICS; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC CORRELATION; GENETIC HETEROGENEITY; GENETIC VARIABILITY; KYPHOSIS; MARFAN SYNDROME; MOUSE; NONHUMAN; PATHOGENESIS; PHENOTYPIC VARIATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; STRAIN DIFFERENCE; ANIMAL; ANIMAL EMBRYO; C57BL MOUSE; CELL CULTURE; CYTOLOGY; DISEASE MODEL; FIBROBLAST; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION; GENETICS; GENOTYPE; HUMAN; METABOLISM; MOUSE MUTANT; NUCLEOTIDE SEQUENCE; PATHOLOGY; PHENOTYPE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; BASE SEQUENCE; CELLS, CULTURED; DISEASE MODELS, ANIMAL; EMBRYO, MAMMALIAN; FIBROBLASTS; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION; GENOTYPE; HUMANS; MARFAN SYNDROME; MICE; MICE, 129 STRAIN; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROFILAMENT PROTEINS; PHENOTYPE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 78649772950     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014136     Document Type: Article

References (36)

1. Pyeritz RE (1990) Marfan syndrome. N Engl J Med 323: 987-989.
2. Silverman DI, Gray J, Roman MJ, Bridges A, Burton K, et al. (1995) Family history of severe cardiovascular disease in Marfan syndrome is associated with increased aortic diameter and decreased survival. J Am Coll Cardiol 26: 1062-1067.
3. Pyeritz RE, McKusick VA (1981) Basic defects in Marfan syndrome. N Engl J Med 305: 1011-1012.
4. Gray JR, Bridges AB, Faed MJ, Pringle T, Baines P, et al. (1994) Ascertainment and severity of Marfan syndrome in a Scottish population. J Med Genet 31: 51-54.
5. Kainulainen K, Peltonen L (1991) Marfan gene discovered. Ann Med 23: 395-396.
6. Kainulainen K, Steinmann B, Collins F, Dietz HC, Francomano CA, et al. (1991) Marfan syndrome: no evidence for heterogeneity in different populations, and more precise mapping of the gene. Am J Hum Genet 49: 662-667.
7. Dietz HC, Cutting GR, Pyeritz RE, Maslen CL, Sakai LY, et al. (1991) Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature 352: 337-339.
8. Pyeritz RE (1986) The Marfan syndrome. Am Fam Physician 34: 83-94.
9. Pyeritz RE, Murphy EA, McKusick VA (1979) Clinical variability in the Marfan syndrome(s). Birth Defects Orig Artic Ser 15: 155-178.
10. Hutchinson S, Furger A, Halliday D, Judge DP, Jefferson A, et al. (2003) Allelic variation in normal human FBN1 expression in a family with Marfan syndrome: a potential modifier of phenotype? Hum Mol Genet 12: 2269-2276.
11. Pereira L, Andrikopoulos K, Tian J, Lee SY, Keene DR, et al. (1997) Targetting of the gene encoding fibrillin-1 recapitulates the vascular aspect of Marfan syndrome. Nat Genet 17: 218-222.
12. Sunaga S, Maki K, Komagata Y, Ikuta K, Miyazaki JI (1997) Efficient removal of loxP-flanked DNA sequences in a gene-targeted locus by transient expression of Cre recombinase in fertilized eggs. Mol Reprod Dev 46: 109-113.
13. Gayraud B, Keene DR, Sakai LY, Ramirez F (2000) New insights into the assembly of extracellular microfibrils from the analysis of the fibrillin 1 mutation in the tight skin mouse. J Cell Biol 150: 667-680.
14. Whiteman P, Handford PA (2003) Defective secretion of recombinant fragments of fibrillin-1: implications of protein misfolding for the pathogenesis of Marfan syndrome and related disorders. Hum Mol Genet 12: 727-737.
15. Buoni S, Zannolli R, Macucci F, Ansaldi S, Grasso M, et al. (2004) The FBN1 (R2726W) mutation is not fully penetrant. Ann Hum Genet 68: 633-638.
16. Judge DP, Biery NJ, Keene DR, Geubtner J, Myers L, et al. (2004) Evidence for a critical contribution of haploinsufficiency in the complex pathogenesis of Marfan syndrome. J Clin Invest 114: 172-181.
17. Pereira L, Lee SY, Gayraud B, Andrikopoulos K, Shapiro SD, et al. (1999) Pathogenetic sequence for aneurysm revealed in mice underexpressing fibrillin- 1. Proc Natl Acad Sci U S A 96: 3819-3823.
18. Ng CM, Cheng A, Myers LA, Martinez-Murillo F, Jie C, et al. (2004) TGF-betadependent pathogenesis of mitral valve prolapse in a mouse model of Marfan syndrome. J Clin Invest 114: 1586-1592.
19. Neptune ER, Frischmeyer PA, Arking DE, Myers L, Bunton TE, et al. (2003) Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet 33: 407-411.
20. Sweet A, Erickson RP, Huntington C, Dawson D (1992) A potential animal model for studying CF heterozygote advantage: genetic variation in theophyllineinducible colonic chloride currents among inbred strains of mice. Biochem Med Metab Biol 47: 97-102.
21. Otsuru S, Hofmann TJ, Rasini V, Veronesi E, Dominici M, et al. (2010) Osteopoietic engraftment after bone marrow transplantation: Effect of inbred strain of mice. Exp Hematol.
22. Yang T, Huang YG, Ye W, Hansen P, Schnermann JB, et al. (2005) Influence of genetic background and gender on hypertension and renal failure in COX-2-deficient mice. Am J Physiol Renal Physiol 288: F1125-1132.
23. Wheeler FC, Fernandez L, Carlson KM, Wolf MJ, Rockman HA, et al. (2005) QTL mapping in a mouse model of cardiomyopathy reveals an ancestral modifier allele affecting heart function and survival. Mamm Genome 16: 414-423.
24. Dietrich WF, Lander ES, Smith JS, Moser AR, Gould KA, et al. (1993) Genetic identification of Mom-1, a major modifier locus affecting Min-induced intestinal neoplasia in the mouse. Cell 75: 631-639.
25. Pu WT (2009) Identification of a cardiac disease modifier gene using forward genetics in the mouse. PLoS Genet 5: e1000643.
26. Booms P, Tiecke F, Rosenberg T, Hagemeier C, Robinson PN (2000) Differential effect of FBN1 mutations on in vitro proteolysis of recombinant fibrillin-1 fragments. Hum Genet 107: 216-224.
27. Rakyan VK, Blewitt ME, Druker R, Preis JI, Whitelaw E (2002) Metastable epialleles in mammals. Trends Genet 18: 348-351.
28. Judge DP, Dietz HC (2008) Therapy of Marfan syndrome. Annu Rev Med 59: 43-59.
29. Sukoyan MA, Kerkis AY, Mello MR, Kerkis IE, Visintin JA, et al. (2002) Establishment of new murine embryonic stem cell lines for the generation of mouse models of human genetic diseases. Braz J Med Biol Res 35: 535-542.
30. Zangala T (2007) Isolation of genomic DNA from mouse tails. J Vis Exp. 246 p.
31. Hogan A, Beddington R, Constantine F, Lacy E (1994) Manipulating the mouse Embryo: a laboratory manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.
32. Reinhardt DP, Keene DR, Corson GM, Poschl E, Bachinger HP, et al. (1996) Fibrillin-1: organization in microfibrils and structural properties. J Mol Biol 258: 104-116.
33. Andrikopoulos K, Liu X, Keene DR, Jaenisch R, Ramirez F (1995) Targeted mutation in the col5a2 gene reveals a regulatory role for type V collagen during matrix assembly. Nat Genet 9: 31-36.
34. Muraishi H [Fundamental of medical image processing with personal computer system-development of Plugins by ImageJ]. Nippon Hoshasen Gijutsu Gakkai Zasshi 66: 260-264.
35. Dunnill MS (1962) Quantitative Methods in the Study of Pulmonary Pathology. Thorax 17: 320-328.
36. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408.